<DOC>
	<DOCNO>NCT01731600</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate safety , efficacy pharmacokinetics ( exposure trial drug body ) NNC 0129-0000-1003 ( N8-GP ) child severe haemophilia A undergone treatment previous factor VIII ( FVIII ) product .</brief_summary>
	<brief_title>A Multinational , Open-Label , Non-Controlled Trial Safety , Efficacy Pharmacokinetics NNC 0129-0000-1003 Previously Treated Paediatric Patients With Severe Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient severe congenital haemophilia A ( FVIII activity level 1 % ) Weight equal 10 kg Documented history 150 exposure day ( ED ) FVIII product patient age 611 year 50 ED FVIII product patient age 05 year Any history FVIII inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>